Darunavir (DRV) is a best in class protease inhibitor commonly used in high-income markets, and has recently been prequalified by the WHO as a fixed-dose-combination with ritonavir (RTV) at a price of US $17.50/pack (EXW) for use in second-line in low- and middle-income countries. CHAI is pleased to share a set of resources to support national decision-making and implementation of this optimal product. Please contact hivtoolkit@clintonhealthaccess.org with any questions about the resources listed here.